Introduction {#s1}
============

It was reported that there were about 12.7 million new cancer cases and 7.6 million cancer deaths through out the world in 2008 [@pone.0090931-Ferlay1]. However, the etiology of cancer remains unknown and disease-modifying treatments are limited. In addition, since the involvement of cytokines in cancer was hypothesized, there were many candidate genes approaching in designing a case-control association study of single nucleotide polymorphisms (SNPs) including p53-binding protein 1 (TP53BP1).

TP53BP1 gene has played an important role in both DNA repair and cell cycle control and also mediates the DNA damage checkpoint through cooperation with damage sensors and signal transducers [@pone.0090931-Miwa1]. The TP53BP1 contains two BRCA1 C-terminal (BRCT) domains, which are essential for tumor suppressor functions [@pone.0090931-Williams1]. The SNPs for TP53BP1 gene may play an important role in the etiology of cancer because of a direct role of TP53BP1 in the cellular response to DNA damage. Previous researches have revealed that no association between TP53BP1 Asp353Glu (rs560191) SNPs and cancer risk [@pone.0090931-Naidu1]--[@pone.0090931-Oliveira1], but Kiyohara et al. reported that the Glu/Glu genotype of TP53BP1 Asp353Glu was associated with a decreased risk of lung cancer [@pone.0090931-Kiyohara1]. So the results of studies concerning association between Asp353Glu (rs560191) polymorphism in TP53BP1 gene and risk of cancer are conflicting.

Considering a single study may lack the power to provide a reliable conclusion, we performed a meta-analysis on these eligible studies to investigate the precise relationship between TP53BP1 Asp353Glu (rs560191) polymorphism and susceptibility to cancer, which would have a much greater possibility of reaching reasonably strong conclusions.

Methods {#s2}
=======

Selection of Eligible Studies {#s2a}
-----------------------------

We searched Medline (US National Library of Medicine, Bethesda, MD), Embase, the Cochrane Library, Chinese Biological Medicine, China National Knowledge Infrastructure, Wang Fang Data and Chongqing VIP database (Last search was updated on December 20, 2013) using the terms "p53-binding protein 1 or TP53BP1 or 53BP1", "Asp353Glu or rs560191 or D353E", "cancer or tunor or carcinoma" and "polymorphism, variant or mutation". The selection was done without restriction on language, but we only included published articles written in English or Chinese. We used the PubMed option "Related Articles" for each study to retrieve additional potentially relevant articles. Reference lists were checked and researchers were contacted for additional literatures.

Selection Criteria {#s2b}
------------------

Studies were selected if they met the following criteria: (1) association study with a case-control or cohort design; (2) the study investigated the association between TP53BP1 (rs560191) polymorphism and the risk of cancer; (3) in the case of multiple publications from the same study group, the most complete and recent results were used.

Exclusion Criteria {#s2c}
------------------

The exclusion criteria were defined as: 1) abstracts, reviews and animal studies; 2) useless data reported, genotype number or frequency not included; and 3) study without sufficient data for meta-analysis. If more than one study was published by the same authors using the same case series, only the most recent study or the study with the largest size of samples was included in our meta-analysis.

Data Extraction {#s2d}
---------------

Two reviewers (Lei Liu and Jinghua Jiao) independently scrutinized studies on the associations between TP53BP1 Asp353Glu (rs560191) polymorphism and risk of cancer. When discrepancies were appeared, all investigators were recruited to assess the data. The following information was collected: First author, publication year, location, ethnicity, sample sizes of patients and controls, study design and genotype numbers.

The reviewers developed a quality assessment scale ([Table 1](#pone-0090931-t001){ref-type="table"}), which was modified from previous studies [@pone.0090931-Liu1]--[@pone.0090931-Gao1], to evaluate the quality of eligible studies.

10.1371/journal.pone.0090931.t001

###### Scale for quality assessment.

![](pone.0090931.t001){#pone-0090931-t001-1}

  Paramete                                                 Score
  ------------------------------------------------------- -------
  Source of cases                                         
  Selected from population o rcancer registry                2
  Selected from oncology department or cancer institute      1
  No description                                             0
  Representativeness of controls                          
  Population-based                                           2
  Population-hospital mixed                                 1.5
  Hospital-based                                             1
  No description                                             0
  Diagnosis of cancer                                     
  Histological or pathologically confirmed                   2
  Patient medical record                                     1
  No description                                             0
  Specimens of cases for genotyping                       
  Peripheral blood or normal tissues                         2
  Tumor tissues or exfoliated cells                          1
  No description                                             0
  Quality control of genotyping                           
  Different genotyping assays confirmed the result           2
  Quality control by repeated assay                          1
  No description                                             0
  Total sample size                                       
  \>1000                                                     2
  200--1000                                                  1
  \<200                                                      0

The review and analysis were guided to conduct by the PRISMA statement for preferred reporting of systematic review and meta-analysis [@pone.0090931-Moher1].

Statistical Analysis {#s2e}
--------------------

Odds ratios (ORs) with 95% confidence intervals (CIs) for genotypes and alleles were used to assess the strength of association between TP53BP1 Asp353Glu (rs560191) polymorphism and risk of cancer. The ORs were performed for the allele contrasts, additive genetic model, as well as recessive genetic model and dominant genetic model, respectively. Heterogeneity was examined with *I^2^* statistic interpreted as the proportion of total variation contributed by between-study variation. We also measured the effect of heterogeneity using a quantitative measure, *I^2^* = 100%×(Q−d f)/Q. If there was a statistical difference in terms of heterogeneity (P\<0.10, *I^2^\>50%*), the random effects model would be used to estimate the pooled ORs [@pone.0090931-DerSimonian1], [@pone.0090931-DerSimonian2]. Otherwise, the pooled ORs were estimated by the fixed effects model [@pone.0090931-Mantel1]. Sensitivity analysis was carried out by deleting one single study each time to examine the influence of individual data set on the pooled ORs. The possible publication bias was assessed with funnel plots and Egger's test. An asymmetric plot suggests a possible publication bias and the P value of Egger's test less than 0.05 was considered representative of statistically significant publication bias [@pone.0090931-Egger1]. All statistical tests were performed with RevMan version 5.0 (Review Manager, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2010) and Comprehensive Meta-Analysis software version 2.0 (Biostat, Englewood Cliffs, I.N.J., USA). *P* value of smaller than 0.05 for any test was considered to be statistically significant.

Results {#s3}
=======

Study Inclusion and Characteristics {#s3a}
-----------------------------------

As showed in [Figure 1](#pone-0090931-g001){ref-type="fig"}, a total of seven studies were included in this meta-analysis including 3,213 cases and 3,849 controls [@pone.0090931-Naidu1]--[@pone.0090931-Kiyohara1]. The studies identified and their main characteristics were summarized in [Table 1](#pone-0090931-t001){ref-type="table"} and [Table 2](#pone-0090931-t002){ref-type="table"}. Genotype distribution of six studies polymorphism did not differ from Hardy-Weinberg equilibrium with in control groups (all were greater than 0.05, [Table 3](#pone-0090931-t003){ref-type="table"}).

![Flow chart demonstrating those studies that were processed for inclusion in the meta-analysis.](pone.0090931.g001){#pone-0090931-g001}
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###### Characteristics of the Included Studies for Meta-analysis.

![](pone.0090931.t002){#pone-0090931-t002-2}

  first author    publicationyear   location   ethnicity                   Histology                   study design           adjusted            Genotypingmethod                         TP53BP1 polymorphism                          cases(n)   controls(n)   Qualityscore
  -------------- ----------------- ---------- ----------- ------------------------------------------- -------------- --------------------------- ------------------ ------------------------------------------------------------------- ---------- ------------- --------------
  Frank B              2005         Germany    Caucasian                 breast cancer                    HB, CC                 No                    Taqman              D353E (rs560191),G412S (rs689647),K1136Q (rs2602141)            353          960            10
  Ma H                 2006          China       Asian                   breast cancer                    HB, CC                 No                     PCR          T-885G (rs1869258), Glu353 Asp(rs560191), Gln1136 Lys (rs2602141)     404          472            9
  Chen K               2007           USA      Caucasian   squamous cellcarcinoma of thehead andneck      HB, CC          age,sex,ethnicity             PCR          T-885G (rs1869258), Glu353 Asp(rs560191), Gln1136 Lys (rs2602141)     818          821            10
  Kiyohara C           2010          Japan       Asian                    lung cancer                     HB, CC                 No                    Taqman                              Asp353 Glu (rs560191)                           462          379            9
  Naidu R              2011         Malaysia     Asian                   breast cancer                    HB, CC                 age                    PCR                      T-885G (rs1869258), Glu353 Asp(rs560191)                  387          252            9
  Oliveira S           2012         Portugal   Caucasian                cervical cancer                   HB, CC                 No                    Taqman                                D353E (rs560191)                              149          280            9
  Zhang H              2013          China       Asian                    lung cancer                     HB, CC      gender,age,smoking status        Taqman         Glu353 Asp (rs560191), Gln1136 Lys(rs2602141),G412S (rs689647)       640          685            10

HB,hospital based; CC, case-comtrol; PCR, polymerase chain reaction.

10.1371/journal.pone.0090931.t003

###### Distributions of TP53BP1 Genotype and Allele among Cases and Controls.

![](pone.0090931.t003){#pone-0090931-t003-3}

  first author    study groups   Distribution of TP53BP1 genotypes               Frequency of TP53BP1 alleles         HWE for control
  -------------- -------------- ----------------------------------- ----- ----- ------------------------------ ----- -----------------
  Chen K              case                      427                  322   69                1176               460        0.45
                    control                     424                  323   74                1171               471        0.27
  Frank B             case                      165                  148   30                478                208        0.69
                    control                     453                  405   94                1311               593         0.8
  Kiyohara C          case                      174                  231   57                579                345        0.14
                    control                     110                  188   81                408                350        0.96
  Ma H                case                      131                  194   77                456                348        0.73
                    control                     144                  237   85                525                407        0.46
  Naidu R             case                      160                  189   38                509                265        0.09
                    control                     99                   132   21                330                174        0.01
  Oliveira S          case                      21                   63    65                105                193        0.36
                    control                     49                   132   99                230                330        0.66
  Zhang H             case                      112                  322   206               546                734        0.47
                    control                     144                  338   203               626                744        0.88

HWE: Hardy-Weinberg equilibrium.

Quantitative Data Synthesis {#s3b}
---------------------------

As showed in [Table 4](#pone-0090931-t004){ref-type="table"}, meta-analysis of the total studies showed that there was no association between Asp353Glu (rs560191) polymorphism and risk of cancer under all five genetic models in overall population (OR = 0.98, 95% CI = 0.86--1.11 for G versus A; OR = 0.95, 95% CI = 0.71--1.28 for GG versus AA; OR = 0.99, 95% CI = 0.86--1.13 for GG versus AG; OR = 0.97, 95% CI = 0.77--1.23 for recessive model; OR = 0.96; 95% CI = 0.87--1.07 for dominant model) ([Figure 2](#pone-0090931-g002){ref-type="fig"} and [Figure 3](#pone-0090931-g003){ref-type="fig"}). In the subgroup analysis according to ethnicity, cancer type, adjusted with control or not, genotyping methods, HWE and quality score, the results suggested that Asp353Glu (rs560191) polymorphism were not associated with the risk of cancer. There was no significant publication bias according to Begg's and Egger's tests (Begg, p = 0.21; Egger, p = 0.64) and funnel plot ([Figure 4](#pone-0090931-g004){ref-type="fig"}).

![A. Forest plot of the association between cancer and the Glu353Asp (rs560191) mutation in overall population (G vs A).\
[Figure 2](#pone-0090931-g002){ref-type="fig"}.B. Forest plot of the association between cancer and the Glu353Asp (rs560191) mutation in overall population (GG vs AA). [Figure 2](#pone-0090931-g002){ref-type="fig"}.C. Forest plot of the association between cancer and the Glu353Asp (rs560191) mutation in overall population (GG vs AG).](pone.0090931.g002){#pone-0090931-g002}

![A. Forest plot of the association between cancer and the Glu353Asp (rs560191) mutation in overall population (GG vs AG+AA).\
[Figure 3](#pone-0090931-g003){ref-type="fig"}.B. Forest plot of the association between cancer and the Glu353Asp (rs560191) mutation in overall population (GG+AG vs AA).](pone.0090931.g003){#pone-0090931-g003}

![Funnel plot analysis on the detection of publication bias in the meta-analysis of the associations between Glu353Asp (rs560191) mutation and cancer risk.](pone.0090931.g004){#pone-0090931-g004}
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###### Summary ORs and 95% CI of the rs560191 Polymorphism in the TB53BP1 Gene and Cancer Risk.

![](pone.0090931.t004){#pone-0090931-t004-4}

  Studygroups            Variables     AlleleModel                                       Codominantmodel                                                                                           Recessivemodel                                      Dominantmodel                 
  --------------------- ----------- ------------------ -------- ---- ------------------ ------------------ ---------- ---- ------------------ ------------------ ------- ---- ------------------ ------------------ -------- ---- ------------------ ------------------ ------- ---- ------------------
  Overall                    7       0.98(0.91--1.05)   0.005    68   0.98(0.86--1.11)   0.96(0.82--1.12)    0.003     70   0.95(0.71--1.28)   0.99(0.86--1.13)   0.07    48   0.98(0.80--1.20)   0.99(0.86--1.12)   0.009    65   0.97(0.77--1.23)   0.96(0.87--1.07)    0.1    43   0.96(0.84--1.11)
  Ethnicity                                                                                                                                                                                                                                                                          
  Caucasian                  3       1.01(0.90--1.12)    0.22    34   1.02(0.89--1.18)   1.00(0.78--1.28)     0.29     19   1.01(0.76--1.34)   1.03(0.81--1.30)   0.29    20   1.03(0.79--1.35)   0.86(0.71--1.04)   0.004    77   0.88(0.58--1.31)   1.00(0.86--1.16)   0.64    0    1.00(0.86--1.16)
  Asian                      4       0.96(0.87--1.05)   0.002    80   0.94(0.76--1.16)   0.93(0.77--1.13)    0.0007    82   0.90(0.55--1.47)   0.97(0.81--1.15)   0.03    66   0.95(0.69--1.31)   0.96(0.82--1.13)   0.004    78   0.92(0.63--1.34)   0.93(0.80--1.08)   0.03    67   0.92(0.72--1.19)
  Cancer type                                                                                                                                                                                                                                                                        
  Breast cancer              3       0.98(0.87--1.10)    0.98    0    0.98(0.87--1.10)   0.97(0.75--1.27)     0.8      0    0.98(0.75--1.27)   1.05(0.82--1.35)   0.57    0    1.05(0.82--1.36)   1.02(0.80--1.30)    0.66    0    1.02(0.80--1.30)   0.95(0.81--1.12)   0.92    0    0.95(0.81--1.12)
  Lung cancer                2       0.94(0.83--1.06)   0.0001   93   0.89(0.55--1.43)   0.88(0.69--1.13)   \<0.0001   94   0.77(0.27--2.21)   0.89(0.72--1.10)   0.008   86   0.80(0.43--1.46)   0.90(0.74--1.10)   0.0005   92   0.77(0.36--1.66)   0.94(0.77--1.14)   0.002   89   0.92(0.50--1.69)
  Others                     2       1.03(0.90--1.18)    0.1     63   1.08(0.83--1.41)   1.06(0.78--1.43)     0.16     50   1.12(0.69--1.81)   1.10(0.83--1.45)   0.18    44   1.11(0.76--1.62)   1.11(0.85--1.44)    0.12    58   1.13(0.75--1.70)   1.01(0.84--1.21)   0.35    0    1.01(0.84--1.21)
  Study with matching                                                                                                                                                                                                                                                                
  Yes                        3       1.04(0.94--1.14)    0.35    4    1.04(0.94--1.15)   1.12(0.90--1.39)     0.36     1    1.12(0.90--1.40)   1.05(0.86--1.27)   0.67    0    1.05(0.86--1.27)   1.07(0.90--1.29)    0.61    0    1.07(0.90--1.29)   1.03(0.90--1.19)   0.25    27   1.04(0.87--1.23)
  No                         4       0.92(0.83--1.02)   0.003    78   0.94(0.75--1.18)   0.81(0.65--1.01)    0.004     78   0.86(0.53--1.39)   0.92(.76--1.13)    0.02    70   0.93(0.64--1.35)   0.90(0.74--1.09)   0.003    79   0.91(0.60--1.38)   0.89(0.77--1.04)   0.12    49   0.90(0.72--1.13)
  Genotyping                                                                                                                                                                                                                                                                         
  PCR                        3       0.98(0.88--1.09)    0.99    0    0.98(0.88--1.09)   0.98(0.77--1.25      0.86     0    0.98(0.77--1.25)   1.05(0.84--1.33)   0.65    0    1.05(0.83--1.33)   1.02(0.82--1.28)    0.72    0    1.02(0.82--1.28)   0.95(0.82--1.10)   0.92    0    0.95(0.82--1.10)
  Taqman                     4       0.98(0.89--1.08)   0.0003   84   0.98(0.77--1.26)   0.94(0.77--1.15)    0.0002    84   0.93(0.54--1.60)    0.95(0.801.13)    0.02    71   0.93(0.66--1.31)   0.97(0.82--1.14)   0.001    81   0.93(0.62--1.39)   0.98(0.84--1.13)   0.02    71   0.99(0.74--1.33)
  HWE                                                                                                                                                                                                                                                                                
  Yes                        9       0.98(0.91--1.05)   0.002    73   0.98(0.84--1.13)   0.95(0.81--1.11)    0.002     74   0.94(0.68--1.30)   0.97(0.84--1.12)   0.05    54   0.96(0.77--1.19)   0.97(0.85--1.12)   0.006    70   0.95(0.74--1.23)   0.97(0.87--1.08)   0.06    52   0.97(0.82--1.15)
  No                         1       0.99(0.78--1.25)     NA     NA   0.99(0.78--1.25)   1.12(0.62--2.02)      NA      NA   1.12(0.62--2.02)   1.26(0.71--2.25)    NA     NA   1.26(0.71--2.25)   1.20(0.96--2.09)     NA     NA   1.20(0.96--2.09)   0.92(0.66--1.27)    NA     NA   0.92(0.66--1.27)
  Score                                                                                                                                                                                                                                                                              
  \> = 10                    3       1.03(0.93--1.13)    0.29    19   1.03(0.92--1.14)   1.06(0.86--1.31)     0.23     32   1.05(0.81--1.36)   0.99(0.83--1.20)    0.7    0    1.00(0.83--1.20)   1.03(0.86--1.22)    0.49    0    1.03(0.86--1.23)   1.04(0.91--1.19)   0.31    16   1.04(0.90--1.21)
  \<10                       4       0.92(0.82--1.02)   0.003    78   0.95(0.75--1.21)   0.84(0.67--1.06)    0.003     79   0.91(0.53--1.55)   0.98(0.79--1.20)   0.01    72   1.01(0.67--1.52)   0.94(0.77--1.14)   0.002    80   0.97(0.61--1.53)   0.86(0.73--1.01)   0.17    41   0.88(0.70--1.10)

P~h~, P-value for test of heterogeneity; HWE: Hardy-Weinberg equilibrium; PCR, polymerase chain reaction; OR: odds ratio; CI: confidence interval.

Sensitivity Analysis {#s3c}
--------------------

According to sensitivity analysis, the results showed us that there was no substantial modification of our estimates after exclusion of individual studies, indicating that the results were stable (data not shown).

Discussion {#s4}
==========

It is well known that SNPs may contribute to an individual's susceptibility to cancer and TP53BP1 is a key component in the cellular response to DNA damage [@pone.0090931-Haffty1]. Therfore, the SNPs of TP53BP1 may play an important role in the etiology of cancer. The conclusion that TP53BP1 gene played an important role in DNA repair has been well-researched, but the functional relevance of TP53BP1 gene polymorphism has not been reported. It is possible that the sequence variation in the promoter and coding region of TP53BP1 might affect its transcription and downstream biological function [@pone.0090931-Naidu1], [@pone.0090931-Chen1].

To the best of our knowledge, some researches that aim at the role of Asp353Glu (rs560191) polymorphism in cancer risk have been performed, but the results are controversial. In order to evaluate on the association between the Asp353Glu (rs560191) polymorphism and cancer risk, we performed this meta-analysis.

We have not found a sinificant association between TP53BP1 Asp353Glu (rs560191) polymorphism and cancer risk in overall population, but different ethnicity, study design, genotyping methods and cancer type would be responsible for the negtive conclusions. We perfomed subgroup analysis based on these factors. However, the resluts showed us that Asp353Glu (rs560191) polymorphism were not associated with the risk of cancer according to ethnicity, cancer type, study with matching or not, genotyping methods, HWE and study score. That may be because only one study [@pone.0090931-Kiyohara1] reported that the Asp353Glu polymorphism was associated with a risk of cancer. Therefore, further studies are needed to confirm our results.

Some studies indicate that TP53BP1 variants may have protective effects on squamous cell carcinoma of the head and neck (SCCHN) risk but such effects were confined to TP53 Arg72Pro variant allele/haplotype carriers [@pone.0090931-Chen1], [@pone.0090931-Zhang1]. As the reason for few studies were perfomed and there were many meta-analysis related on TP53 Arg72Pro polymorphism and cancer risk [@pone.0090931-Weng1], [@pone.0090931-Zhao1], we could not use meta-analysis to analyze the relationship between TP53BP1 Asp353Glu (rs560191) polymorphism combined with TP53 gene polymorphism and cancer. In addition, Rudd et al. [@pone.0090931-Rudd1] and Truong et al. [@pone.0090931-Truong1] found that Asp353Glu (rs560191) polymorphism was associated with lung cancer risk, but this association was not been found in the study [@pone.0090931-Brooks1] by Brooks JD et al. In addition, because lack of sufficient data from these three studies, we could not include these studies in this meta-analysis. That may be another reason for the negtive conclusion in this meta-analysis.

The meta-analysis by Timofeeva et al. [@pone.0090931-Timofeeva1] did not show a significant association between rs560191 polymorphism and lung cancer risk. It came to the same conclusion with our study. However, it was only concerned lung cancer risk. In our meta-analysis, the association between rs560191 polymorphism and other cancer types including cervical cancer, breast cancer and squamous cell carcinoma of the head and neck was also analyzed.

There are several limitations in this meta-analysis that should be considered. First, cancer is a multi-factorial disease including complex interactions from environmental exposure to gene factors. In this meta-analysis, we had insufficient data to perform an evaluation of such interactions for the independent role of TP53BP1 Asp353Glu (rs560191) polymorphism in cancer development. Second, only seven studies were included in this meta-analysis. Thus, more studies are needed to identify this association more comprehensively. Third, study by Naidu et al. [@pone.0090931-Naidu1] showing genotype distributions of the control population that were not in HWE was included in this meta-analysis. Forth, we did not consider studies published in languages other than English/Chinese or data presented in abstracted form; thus, publication and potential language biases may occur.

In conclusion, this meta-analysis suggested that the polymorphism in TP53BP1 Asp353Glu (rs560191) gene could not be regarded as a genetic risk factor for cancer. At the same time, this result should be interpreted cautiously. To verify this result, large scale case-control studies with detailed individual information are needed.
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